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CD157, known as bone marrow stromal cell antigen-1, is a glycosylphosphatidylinositol-
anchored ADP-ribosyl cyclase that supports the survival and function of B-lymphocytes and
hematopoietic or intestinal stem cells. Although CD157/Bst1 is a risk locus in Parkinson’s
disease (PD), little is known about the function of CD157 in the nervous system and
contribution to PD progression. Here, we show that no apparent motor dysfunction
was observed in young knockout (CD157−/−) male mice under less aging-related effects
on behaviors. CD157−/− mice exhibited anxiety-related and depression-like behaviors
compared with wild-type mice. These behaviors were rescued through treatment with
anti-psychiatric drugs and oxytocin. CD157 was weakly expressed in the amygdala and
c-Fos immunoreactivity in the amygdala was less evident in CD157−/− mice than in
wild-type mice. These results demonstrate for the first time that CD157 plays a role as
a neuro-regulator and suggest a potential role in pre-motor symptoms in PD.
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INTRODUCTION
Parkinson’s disease (PD) is considered to be amovement disorder,
and its diagnosis is based on the presence of a set of cardinalmotor
symptoms (Samil et al., 2004; Jankovic, 2008). Recently, consider-
able evidence has shown that the neurodegenerative processes that
lead to sporadic PD begin many years before the appearance of
the characteristic motor symptoms associated with nigro-striatal
dopaminergic neuron loss (Leentjens et al., 2011; Noyce et al.,
2012; Prediger et al., 2012). Thus, abnormalities in additional
neuronal regions, including the amygdala, are potentially involved
in PD progression and may contribute to the appearance of non-
motor symptoms (Tessitore et al., 2002; Hälbig et al., 2011), such
as anxiety, depression, olfactory and memory impairment, sleep
abnormalities and gastrointestinal disturbances (Menza et al.,
1993; Chaudhuri et al., 2006; Reijnders et al., 2008; Chaudhuri
and Schapira, 2009). Anxiety and depression are the earliest PD
manifestations, and patients with high anxiety are at an increased
risk for PD (Frisina et al., 2009; Bower et al., 2010; Nègre-Pagès
et al., 2010). The underlying biological mechanisms that lead to
these symptoms during any stage of the disease, including the
pre-motor phase, are unknown (Richard, 2005; Tadaiesky et al.,
2008; Siderowf and Lang, 2012; Pontone et al., 2013).
Interestingly, genome-wide association studies and
meta-analysis for PD have identified intronic single-nucleotide
polymorphisms (SNPs) in the CD157/BST1 gene on human
chromosome 4p15 as new susceptibility loci in several popula-
tions (Satake et al., 2009; Tan et al., 2010; Liu et al., 2011, 2013b;
Nalls et al., 2011; Saad et al., 2011; Simón-Sánchez et al., 2011;
Spencer et al., 2011; Zimprich, 2011; Lill et al., 2012; Sharma
et al., 2012), with reported variations (Chang et al., 2011; Miyake
et al., 2012; Wang et al., 2012; Zhu et al., 2012; Chen et al., 2013;
Chung et al., 2013). These studies indicate that CD157 might be
associated with the causality of PD, or at least one of a variety of
PD symptoms.
Bone marrow stromal cell antigen-1 (BST-1) was first isolated
as a cell surface molecule that supports the pre-B cell growth
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with enhanced expression on the bone marrow stromal cell lines
derived from rheumatoid arthritis patients (Kaisho et al., 1994;
Ishihara and Hirano, 2000). BST-1 was also expressed on myeloid
cells as a molecule capable of signal transduction and clustered in
CD157 in Leucocyte Typing IV after genetic cloning (Itoh et al.,
1994; Muraoka et al., 1996; Okuyama et al., 1996; Ishihara et al.,
1997). CD157/BST-1 is a member of the NADase/ADP-ribosyl
cyclase family, which includes CD38 (Hirata et al., 1994; Itoh et al.,
1994; Ferrero et al., 1999; Ishihara and Hirano, 2000; Guse, 2005;
Malavasi et al., 2006, 2008; Lee, 2012;Quarona et al., 2013). CD157
plays a variety of roles in humoral immune responses, neutrophil
transmigration and haematopoietic stem cell support (Ishihara
andHirano, 2000; Funaro et al., 2004; Podestà et al., 2005;Malavasi
et al., 2006; Mouchiroud et al., 2013). CD157 is also involved in
the pathophysiology of various diseases, such as the survival of
B cells in rheumatoid arthritis, the progression of leukaemia and
metastasis of human ovarian carcinoma cells (Kaisho et al., 1994;
Shimaoka et al., 1998; Ishihara and Hirano, 2000; Ortolan et al.,
2010; Quarona et al., 2013; Lo Buono et al., 2014). In addition,
a new role for CD157 has been reported in stem cells: CD157
induces the catalysis of cyclic ADP-ribose in paneth cells, which
promotes intestinal stem cell self-renewal in mice on a calorie-
restricted diet (Yilmaz et al., 2012); or lung stem/progenitor cells
express CD157 (Wu et al., 2013). However, these reports revealed
little or no information concerning the relationship with brain
function or brain deficits in PD.
In this study, to clarify the neuronal functions of
CD157/BST-1, we attempted to characterize the motor and
social behaviors in young adult (8- to 10-week-old) male CD157
knockout (CD157−/−) mice (Itoh et al., 1998), specifically
while controlling for any aging-related effects on behaviors. We
show that CD157−/− mice exhibit no motor dysfunction, but
severe anxiety-related and depression-like behaviors, which were
reversed through drug treatment.
MATERIALS AND METHODS
ANIMALS
CD157/Bst1 knockout (CD157−/−) mice were previously
described (Itoh et al., 1998). Frozen CD157+/− fertilized oocytes
were routinely inoculated into psuedopregnant foster mothers.
Offspring were genotyped as previously described (Itoh et al.,
1998). CD157−/− mice were maintained by crossbreeding
homozygous mutant mice. C57BL/6 wild-type (CD157+/+) and
CD157−/− mice were maintained at the animal center under
standard conditions (22◦C; 12-h light/dark cycle, lights on
at 8:45 AM) in standard mouse cages (300 × 160 × 110mm)
with sawdust bedding and food and water ad libitum. The
breeding pairs were maintained separately (1 pair per cage).
After parturition, pup body weight of both males and females
was measured daily in 10 pairs containing approximately 40
pups. At 21 days old, the offspring were removed for weaning
and housed in same-sex sibling pairs. Subsequently, viability
was assessed. All animal experiments were carried out in accor-
dance with the Fundamental Guidelines for Proper Conduct of
Animal Experiment and Related Activities in Academic Research
Institutions under the jurisdiction of the Ministry of Education,
Culture, Sports, Science and Technology of Japan, and were
approved by the Committee on Animal Experimentation of
Kanazawa University.
RABBIT ANTI-CD157 ANTIBODY
An antibody that specifically recognizes murine CD157 (BST-1)
was used in this study. Anti-murine CD157 antiserum was
prepared by immunizing rabbits with a chimeric fusion pro-
tein of murine CD157 and the Fc portion of human IgG1
(mBST-1Fc), and the reactivities to human IgG andmurine CD38
were absorbed by human IgG sepharose 6 and the transfectant,
BAFmCD38, respectively (Kajimoto et al., 1996). In some exper-
iments involving histochemical staining in the brain, we also
used CD157mAb (clone BP-3; Becton Dickinson, NJ, USA). We
obtained identical staining results from both antibodies.
Adult mice were sacrificed through transcardial perfusion
with 4.0% paraformaldehyde in phosphate buffered saline (PBS,
Gibco, Life Technologies, Tokyo). Subsequently, the spleen was
removed, fixed overnight and cryoprotected in PBS containing
15 and 30% sucrose. The spleen was cut into 20-μm-thick sec-
tions using a freezing microtome. The sections were washed in
PBS to wash out the OCT compound and permeabilised with
0.3% TritonX-100 in PBS for 30min. Subsequently, the sections
were blocked in PBS containing 0.3% TritonX-100 and 3% BSA
(bovine albumin, F-V, pH 5.2; Nacalai Tesque, Kyoto, Japan)
for 1 h at room temperature and incubated for 2 nights at 4◦C
with primary anti-murine CD157 antiserum (1:100). The sec-
tions were washed with 0.3% TritonX-100 in PBS and incubated
with goat anti-rabbit IgG Alexa Fluor 488 (Invitrogen Molecular
Probes; Tokyo, Japan; 1:200) and DAPI (Dojindo, Kumamoto,
Japan; 1:2000) for 1 h at room temperature. Imaging was per-
formed with an Olympus IX71 fluorescence microscope (Tokyo,
Japan).
FOOTPRINT PATTERN ANALYSIS
The footprint test was used to compare the gaits of CD157+/+
and CD157−/− mice (Steele et al., 2007). Hindfeet and forefeet
were coated with a black non-toxic paint, and the animals were
allowed to walk along a 50-cm-long, 10-cm-wide runway (with
15-cm high walls) over a fresh sheet of white paper (Nóbrega
et al., 2013). The distance between the center of the hindfoot print
and the center of the preceding forefoot print was recorded over a
sequence of 4 consecutive steps, excluding footprints made at the
beginning and end of the run. Two operators made all footprint
recordings for 20 mice.
ROTA ROD TEST
To investigate the motor coordination/motor learning abilities,
the accelerating rota rod paradigm was used (Yoshihara et al.,
2009; Ito et al., 2012). The mice were tested in 3 trials per day for
3 consecutive days with a 300-sec accelerating programme (from
5 to 40 rpm). The latency to fall from the rod was calculated.
HOMECAGE ACTIVITY
Mouse spontaneous activity in a familiar environment was
recorded using a homecage activity monitoring system (The
SmartCage system, O’Hara & Co., LTD. Tokyo, Japan). A 12-h
light/dark cycle and LED illumination were programmed (08:45–
20:45, light period; 20:45–08:45, dark period). Each mouse was
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separately housed in a cage, and the mice could access water
and food pellets ad libitum. The floor size of each homecage was
17 × 25 cm and was illuminated at 50 lux in the light period.
Mouse movement was recorded for 24 h (Steele et al., 2007).
OPEN FIELD TEST
The open field test measures locomotion and anxious behaviors
(Silverman et al., 2013). The open field box consisted of a square
box (600 × 600 × 200mm), covered with polypropylene sheets
inside the wooden box. The center arena (300 × 300mm) was
outlined. Each animal was placed in the box for 10min. Overall
activity in the box was measured, and the amount of time and
distance traveled in the center arena was noted. The distance trav-
eled in the field was recorded using a digital video system and
ANY-maze software (Stoelting Co., Wood Dale, IL, USA). This
paradigm is based on the idea that mice will naturally prefer to
be near a protective wall rather than exposed to danger out in the
open. After each trial, the test chambers were cleaned with a damp
towel and 1% sodium hypochlorite, followed by 70% alcohol (Liu
et al., 2013a).
SOCIAL PREFERENCE TASK IN THE OPEN FIELD
This test was performed in the open field chamber. A mouse
was first placed in the open field for 10min (habituation ses-
sion). After habituation, the mouse was returned to its home
cage, and an inanimate object was placed in the center of the
field. In the next test, session 1, the mouse was again placed in
the open field chamber with the novel non-social object (a wire
cage) for next 10min. Subsequently, the non-social object was
changed for a C56BL/6 naïve male mouse under a new wire cage
(70 × 90 × 70mm and bars spaced 5mm apart). The test mouse
was again introduced to the arena for 10min. The percentage of
time spent and the number of entries into the inside zone were
analyzed using the digital video system and the ANY-maze video
tracking software. At the end of each test, the open field box
and inanimate object were sprayed with 1% sodium hypochlorite
and subsequently 70% ethanol and were wiped clean with paper
towels. The mean time interval between sessions was 2–3min.
SOCIABILITY AND PREFERENCE FOR SOCIAL NOVELITY
The social behavior test was performed using a three-chamber
box to assess whether subject mice tend to spend time with
stranger mice. The apparatus was a rectangular, three-chambered
box covered with clear polycarbonate. Dividing walls had door-
ways allowing access into each chamber. At the end of each test,
the apparatus was sprayed with 1% sodium hypochlorite and 70%
ethanol and wiped clean with paper towels. The following proce-
dure was used for the social behavior test: (A) Habituation. The
test mouse was first placed in the middle chamber and allowed to
explore for five minutes with free access to all parts of arena. Each
of the two sides contained an empty wire cage (70 × 90 × 70mm
and bars spaced 5mmapart). (B) Sociability. After habituation, an
unfamiliar mouse (Stranger 1; a naïve C57BL/6 male) was placed
in the wire cage (in the left chamber); another wire cage (in the
right chamber) was empty, and the test mouse was placed in the
center compartment of the social test box and allowed to explore
for a 5-min session, with free access into the two side chambers.
The amount of time spent in each chamber and the number of
entries into each chamber were measured using the digital video
system and ANY-maze software.
SOCIAL AVOIDANCE TEST
Social-avoidance behavior toward a novel C57BL/6 mouse was
measured in a two-stage social-interaction test (Chaudhury et al.,
2013). In the first 10-min test (target absent), the experimen-
tal mouse was allowed to freely explore a square-shaped arena
(600 × 600mm) containing a wire mesh cage (70 × 90 × 70mm
and bars spaced 5mm apart) placed in the center of the arena. In
the second 20-min test, the experimental mouse was reintroduced
back into the arena with an unfamiliar C57BL/6 male mouse in a
wire mesh cage. Video tracking software (ANY-maze) was used
to measure the amount of time the experimental mouse spent in
the “interaction zone” (300 × 300mm). Behavior was measured
in mice at 20min after an intraperitoneal injection of 0.3ml of
oxytocin (OT) (100 ng/kg body weight) or PBS or without any
treatment.
LIGHT-DARK TRANSITION TEST
The light-dark transition was measured using the light-dark test
chamber, as described by Crawley (2008). The chamber consisted
of two dividing rooms. One chamber was brightly illuminated
(250 lux), whereas the other was dark (2 lux). Mice were placed
into the light arena and were allowed to move freely between
the two chambers for 600 s. The light-dark transition test might
be useful to predict anxiolytic-like or anxiogenic-like activity in
mice. It has the advantages of being quick and easy to use, with-
out requiring the prior training of animals. The test box (200 ×
600 × 200mm) consists of a small dark safe compartment (one-
third, 200 × 200 × 200mm—dark box) and a large illuminated
aversive compartment (two-thirds, 400 × 200 × 200mm—light
box). Each male mouse was placed in the center of the light cham-
ber, and the mouse was allowed to run freely between the two
chambers for 10min. To ensure, the reverse paradigm was also
performed: a mouse was placed in the dark chamber first. The
trial was recorded for 10min using the ANY-maze video system.
Latency to enter (defined by all four paws entering), time spent,
entries and distance traveled in the light chamber were recorded.
ELEVATED PLUS MAZE
The elevated plus maze is widely used in the study of anxiety-like
behavior (Lister, 1987). Themaze apparatus was elevated to 50 cm
above the floor and consisted of the central platform (5 × 5 cm),
from which two open arms (5 × 25 cm) and two closed arms
(5 × 25 cmwith 15-cm high transparent walls) extended in oppo-
site directions. At least 30min before each behavioral test, the
mice were transported to the testing room for habituation. At the
initiation of each session, themice were placed on the central plat-
form facing an open arm and were allowed to explore the maze
freely for 5min.
TAIL SUSPENSION TEST
The test was performed according to the method previously
described (Steru et al., 1985). The mice were individually sus-
pended by the tail above the floor and affixed with adhesive tape
placed approximately 1–2 cm from the tip of the tail. The duration
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of immobility was measured for 6min. The duration of immobil-
ity was defined as the time whenmice were completely motionless
and hung passively.
FORCED SWIMMING TEST
The test was performed according to the method described
(Porsolt et al., 1977). Mice were placed individually in a cylinder
(height 25 cm, diameter 15 cm) filled to a 10-cm depth with water
(25 ± 1◦C) for 6min. After the initial 2min of vigorous activ-
ity, the total duration of immobility was recorded during the last
4min of the test. The duration of immobility was defined as the
time during which the mouse remained floating passively, made
no attempts to escape and showed only slow movements to keep
its head above the water.
The duration of climbing behavior was defined as the time
during which the mouse was making forceful thrash movements
with its forelimbs against the walls of cylinder during the 6min.
DRUG TREATMENT
Diazepam was purchased from Wako Pure Chemical Industries,
Ltd. (Osaka, Japan), and mirtazapine was obtained from Meiji
Seika Pharma Co. Inc. (Tokyo, Japan). Both drugs were dissolved
in distilled water with 0.2% of Tween 80. Diazepam was admin-
istered at a dose of 1mg/kg (i.p., 5ml/kg of body mass). For
mirtazapine treatment, themice were treated once daily for 7 con-
secutive days at a dose of 1mg/kg (i.p., 5ml/kg of bodymass). The
mirtazapine behavioral test was performed on the eighth day.
ACOUSTIC STARTLE RESPONSE AND PRE-PULSE INHIBITION
A startle reflex measurement system was used (O’Hara & Co.,
LTD.) to measure startle response and prepulse inhibition. A test
session was initiated after placing a mouse in a plastic cylinder,
where it was left undisturbed for 10min. White noise (120 db,
40ms) was used as the startle stimulus for all trials. The startle
response was recorded for 140ms starting with the onset of the
prepulse stimulus. The background noise level in each chamber
was 70 db. In the startle and prepulse inhibition paradigm, the
prepulse sound was presented 100ms before the startle stimu-
lus. The intensities of the prepulse sounds were 0, 75, 80, 85, and
90 db, and each sound was separately paired with a 120-db startle
sound. The responses in a pair of 0-db prepulse and 120-db startle
sound were employed as an acoustic startle response.
FEAR CONDITIONING
Contextual and cued fear conditionings were measured using
equipment from O’Hara & Co., LTD. Briefly, training and tests
consisted of three trials. During training, the mouse was placed
in a test chamber for 300 s. A 60-db white noise (conditioned
stimulus) was presented for 30-s, followed by a mild (2 s, 0.3mA)
electric footshock, which served as the unconditioned stimulus.
Two more tone-shock stimulus pairings with the same duration
as the first stimulus were presented. Context testing was con-
ducted 24 h after conditioning in the same chamber for 300 s.
Cued testing with an altered context was conducted 24 h after the
contextual test using a different texture and a differently illumi-
nated box. The cued tone (30 s) was presented twice with a 300-s
test duration. The animal movement was recorded using a video
camera on the ceiling, and the duration of freezing was analyzed
using an Image J-based original program.
PHARMACOLOGICAL MODELS OF PARKINSON’S DIEASE
A mouse model of PD was created through intraperitoneal injec-
tions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
(Sigma, St Louis, MO, USA; 20mg/kg) 4 times at 2-h interval
(Kühn et al., 2003). Immunohistochemical and biological analysis
was performed 4 days after MPTP injection. Briefly, the brain was
cut into 10-μm-thick sections using a cryostat. The sections were
blocked in PBS containing 0.3% TritonX-100 and 3% BSA for 1 h
at room temperature and incubated at 4◦C overnight with pri-
mary anti-tyrosine hydroxylase (TH) antibody (Sigma; 1:1000)
and anti-GFAP antibody (Millipore, Billerica, MA, USA; 1:500).
The sections were subsequently washed with 0.3% TritonX-100 in
PBS and incubated with Alexa Fluor 488 (Invitrogen Molecular
Probes; 1:200) and Cy3-labled-IgG (Jackson ImmunoResearch
Laboratories, West Grove, PA, USA; 1:100) for 1 h at room tem-
perature. Imaging was performed with a Nikon EZ-C1 laser
confocal microscope (Tokyo, Japan). TH+ neuronal cells in the
substantia nigra pars compacta (SNpc) were counted in 2 repre-
sentative sections (Bregma −3.16 and −3.64mm) as previously
described (Takano et al., 2007). The statistical analysis was per-
formed using Student’s t-test and One-way or Two-Way ANOVA
followed by Bonferroni/Dunn test.
For western blot analysis, brain samples from the striatum
were solubilized in buffer containing 1% NP40, 0.1% SDS and
0.2% deoxycholate and were subjected to western blotting with
the following antibodies: TH (Sigma), α-synuclein (Santa Cruz),
GFAP (Millipore) and β-actin (Sigma). Primary antibody binding
was visualized using the ECL system (GE Healthcare Bio-Sciences
Corp., Piscataway, NJ, USA). Quantification of each band was
performed using Image J (version 1.42, Wayne Rasband, National
Institutes of Health, MD, USA).
BLOOD AND TISSUE COLLECTION
Male mice were anaesthetized by intraperitoneal injection of pen-
tobarbitone (35mg/Kg). Blood samples of 1ml were collected by
cardiac puncture and centrifuged at 1600× g for 15min at 4◦C.
Plasma samples (∼200–400μl/mouse) were collected and stored
at −80◦C until use.
The whole pituitary and hypothalamus were removed, and
homogenized in 10mM Tris-base (pH 7.4) using a 1-ml
Teflon/glass homogenizer. The fresh homogenates were used for
determining ADP-ribosyl cyclase activity, as described (Jin et al.,
2007).
The whole pituitary and hypothalamus were removed and
homogenized in 0.4M acetic acid, using a 1-ml Teflon/glass
homogenizer. The fresh homogenates were centrifuged at 800× g
for 20min at 4◦C. The supernatants were collected and stored
at −80◦C until measurement of oxytocin. Protein content was
determined using a Bio-Rad protein assay kit and bovine serum
albumin as a standard (Bio-Rad, Hercules, CA, USA).
ENZYME IMMUNOASSAY FOR OXYTOCIN
To determine the concentrations of OT in the plasma and brain
tissues, an OT immunoassay kit was used according to the
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manufacturer’s protocol (Assay Designs Inc., Ann Arbor, MI,
USA), as described previously (Jin et al., 2007).
ADP-RIBOSYL CYCLASE ASSAY
Assay to detect ADP-ribosyl cyclase activity in the hypothalamus
and pituitary was performed in whole homogenates using the
nicotinamide guanine dinucleotide technique as described pre-
viously (Jin et al., 2007; Graeff and Lee, 2013). Briefly, 2ml of
reaction mixtures containing 60μM NGD+, 50mM Tris-HCl,
pH 6.6, 100mM KCl, 10μM CaCl2, were maintained at 37◦C
with constant stirring. The samples were then excited at 300 nm,
and fluorescence emission was continuously monitored at 410 nm
in a Hitachi 650 spectrofluorometer. Activity was calculated from
the linear portion of the 10min time course by fitting a linear
function to the data points recorded every 15 s.
The specific ADP-ribosyl cyclase activity was calculated using
cyclic GDP-ribose (cGDPR) standard, and the results are pre-
sented as nanomoles cGDPR per min per mg of protein.
RT-PCR
Total RNA was isolated frommouse spleens and brain subregions
using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA). cDNA
was synthesized from 0.5μg of total RNA using the ReverTra
Ace-α (Toyobo, Osaka, Japan) according to the manufacturer’s
protocol. PCR was performed on a Mastercycler ep gradient S
(Eppendorf, Hamburg, Germany) using the following conditions:
1 cycle of 94◦C for 30 s, followed by 25 or 30 cycles of 94◦C
for 30 s, 58◦C for 30 s and 72◦C for 40 s, with a final extension
step at 72◦C for 1min. The primer sequences used have been
reported (Itoh et al., 1998). RT-PCR products were separated elec-
trophoretically on 1.2% gels and stained with ethidium bromide.
Band intensity was measured from photographs using Image J.
The data are shown as CD157 intensity divided by the β-actin
intensity of the same sample.
IMMUNOHISTOCHEMISTRY
Prior to immunohistochemical procedures, the brain sec-
tions were washed in PBS and were incubated in PBS con-
taining 0.3% Triton X-100 (Sigma) and 10% normal horse
serum (Invitrogen) for 1 h. Subsequently, sections were incu-
bated with anti-NeuN (1:200; Chemicon, Temecula, CA, USA)
antibody at room temperature for 12 h. The samples were
washed with PBS and incubated with the Alexa Fluor 488
dye (1:200) at room temperature for 3 h. After washing with
PBS, the sections were incubated with 10mg/ml Hoechst
33258 solution (Sigma) for visualization of the nucleus.
Imaging was performed using an Axio Observer.A1 (Zeiss, Jena,
Germany).
The amydgala sections were first incubated with primary
anti-murine CD157 antiserum and subsequently washed with
0.3% TritonX-100 in PBS and incubated with goat anti-rabbit
IgG Alexa Fluor 488 (1:200) and DAPI (Dojindo; 1:2000)
for 1 h at room temperature. Subsequently, the sections were
washed with PBS containing 0.3% TritonX-100 and coverslipped
with anti-fade (Akimoto et al., 2013). Imaging was performed
using an Olympus IX71 microscope. Images were analyzed with
MetaMorph software (Molecular Devices, Downingtown, PA,
USA) (Higashida et al., 2004).
NISSL STAINING
Frozen brain sections were stained with 0.5% thionin acetate
(Nacalai Tesque) at room temperature for 1min. Low-
magnification images were taken with the BZ-9000 Generation II
microscope (Keyence, Osaka, Japan).
c-FOS IMMUNOREACTIVITY
After the 10-min open field test, the mice were sacrificed imme-
diately for brain fixation with 4% paraformaldehyde in PBS
overnight. After the brains were cryoprotected in PBS contain-
ing 15 and 30% sucrose, the brains were cut into 20-μm-thick
sections using a freezing microtome. The sections were processed
as described above and incubated overnight at 4◦C with the
primary antibody c-Fos (Santa Cruz, Dallas, TX, USA; 1:200).
The brain sections were stained with goat anti-rabbit IgG Alexa
Fluor 488 (1:200) and DAPI (1:2000) for 1 h at room tempera-
ture. Subsequently, the sections were washed with PBS containing
0.3% TritonX-100 and coverslipped with anti-fade. Imaging was
performed using an Olympus IX71 microscope. Images were
recorded with MetaMorph software. c-Fos-positive cells were
counted manually using the following parameters: fluorescence
diameters <13.5μm and intensities >498.6 were counted. The
average intensity of fluorescence was within a 5-fold range.
STATISTICAL ANALYSIS
The data are expressed as the means ± s.e.m. The comparisons
were evaluated between two groups (CD157+/+ or CD157−/−)
using Student’s t-test or One-Way ANOVA, followed by post-
hoc Bonferroni test. In all analyses, P < 0.05 indicated statistical
significance.
FIGURE 1 | Motor coordination tests. (A) A representative footprint. The
footprint patterns revealed no impairment of motor coordination in
CD157−/− mice (n = 20). (B) Motor learning and memory was increased
following training (3 trials a day for 3 days) similarly in both types of
CD157+/+ (blue triangles, n = 10) and CD157−/− (red diamonds, n = 20)
mice in the accelerating (5–40 rpm) rota rod paradigm.
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RESULTS
GENERAL HEALTH AND LOCOMOTOR ACTIVITIES
We used CD157−/− mice newly reproduced from frozen
CD157+/− eggs (Itoh et al., 1998). These mice expressed no
CD157 immunoreactivity in the white pulp of the spleen (data
not shown). CD157−/− mice developed normally compared with
wild-type (CD157+/+) C57BL/6 mice and were viable, as pre-
viously described (Itoh et al., 1998), although the weaning rate
of 3- to 4-week-old pups was low (approximately 50% of wild-
type mice). We did not detect skin lesions due to self-injurious
over-grooming behavior in the CD157−/− mice, suggesting no
repetitive behavior.
Paralysis, tremor, rigity, postual abnormality and involuntary
movements were not observed. The CD157−/− mice walked
normally (Figure 1A). When 8- to 10-week-old CD157+/+ and
CD157−/− male mice were subjected to the rota rod test for 3 suc-
cessive days, there were no differences in their motor coordination
and learning (Figure 1B). The latency to fall from the rotating
rod was similar between the two genotypes, suggesting that there
was no weakness in the fore and hind limbs and no coordinate
movement dysfunction.
One of the hallmarks in PD is the degeneration of dopaminer-
gic neurons in the substantia nigra. Therefore, we conducted an
analysis of tyrosine hydroxylase-positive cells by immunohisto-
chemistry or by analysing the mRNA expression level of tyrosine
hydroxylase in both genotypes (Figure 2). Essentially no differ-
ence was found in wild-type and knockout mice. In addition,
when the acutely 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine
(MPTP)-treated loss of tyrosine hydroxylase-positive cells in the
substantia nigra and the striata was examined. MPTP-treated
CD157−/− mice exhibited the same sensitivity as wild-type mice
with regard to nigro-striatal degeneration in the MPTP-induced
PD model. Northern blotting showed that the mRNA expression
level of α-synuclein did not differ between the two MPTP-treated
genotypes (Figure 3). Therefore, the results show that CD157−/−
mice have little to no deficiency in motor learning, memory and
FIGURE 2 | Degeneration of nigro-striatal neurons after MPTP
administration. (A,B) Brain sections, including the substantia nigra (A) or
striata (B) from CD157+/+ (+/+) or CD157−/− (−/−) mice injected with
MPTP or vehicle, were immunostained with anti-tyrosine hydroxylase (TH)
and anti-GFAP antibodies. The numbers of TH+ cells in the substantia nigra
pars compacta were counted and are shown in the graph (A). The values
shown represent the means ± s.e.m. of four experiments. ∗P < 0.05
compared with vehicle-administered mice. Scale bar = 50μm. (C) Protein
extracts from the striata of CD157+/+ or CD157−/− mice that were injected
with MPTP or vehicle were subjected to western blotting with the indicated
antibodies. The relative intensities are shown in the graphs. The intensities of
signals derived from mice with vehicle administration were designated as
one. The values shown represent the means ± s.e.m. of four experiments.
∗P < 0.05 compared with vehicle-administered mice.
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FIGURE 3 | Expression of α-synuclein. (A) Protein extracts from the
ventral midbrain or caudate putamen of CD157+/+ or CD157−/− mice that
were injected with MPTP or vehicle were subjected to western blotting
with anti-α-synuclein antibody and anti-β-actin-antibody. (B) Brain sections
including the substantia nigra pars compacta (SNpc) and reticulate (SNPr)
from CD157+/+ or CD157−/− mice that were injected with MPTP or vehicle
were immunostained with anti-TH antibody and anti-α-synuclein antibody.
10 week-old mice. Scale bar = 50μm.
function in young adulthood, though the more chronic mouse
PD model or aged mice should be used to unravel any possible
long-term effect of altered CD157 function.
Interestingly enough, home cage activity monitoring revealed
that the activity level of the CD157−/− mice during both the day
and night was approximately 40 ± 4% of that of the CD157+/+
mice (n = 8 in each genotype, t = 7.575, P < 0.05; Figure 4).
The day and night rhythms were similar between wild-type and
knockout mice during the time period of 7 days, Therefore, we
estimated that the CD157−/− mice may squat in one place for
long periods of time, which may lead to decreases in total motor
activities in daily life. Because this characteristic behavior seems
to be derived from specific emotional conditions, we assessed
their psychological responses in a series of emotion-related social
behavior tests.
BEHAVIORS DURING EXPOSURE TO NOVELTY
When mice were exposed to the novel environment in the
open field apparatus (Figure 5A), judging from the observed
tracks traveled, CD157−/− male mice engaged less in exploratory
behavior, particularly in the inside zone, than wild-type males
(Figures 5B,C). Although there was little to no behavioral dif-
ference observed in the outside zone (data not shown), the
percentage of time in the inside zone was reduced for CD157−/−
mice (n = 8, t = 3.144, P < 0.01; Figure 5D). CD157−/− mice
entered the inside zone fewer times than did CD157+/+ mice
(n = 8, t = 2.613, P < 0.05; Figure 5E). In contrast, the average
FIGURE 4 | Spontaneous homecage activity in CD157+/+ (A) and
CD157−/− (B) mice. Activity was monitored in a 24 h record for 7 days
(n = 8, each genotype). Higher activity levels indicate the dark phase during
a 12:12 light:dark cycle (lights on at 8:45 AM; lights off at 8:45 PM).
speed of the CD157−/− mice in the inside arena was higher
than that of the wild-type mice (n = 8, t = 2.127, ∗P < 0.05;
Figure 5F).
We performed social interaction and preference tests with
novel non-social or social targets in the same open field appara-
tus. First, using a non-social object (Figures 5G–I), we confirmed
that the CD157−/− male mice exhibited a higher level of anxiety
due to their reduced entry into the inside zone (n = 8, t = 4.593,
P < 0.01; Figure 5M). The percentage of time spent close to the
non-social object in the inside zone was significantly shorter
for CD157−/− mice than for CD157+/+ mice (n = 8, t = 3.822,
P < 0.01; Figure 5N). When an unknown male mouse was used
as a social stimulus (Figures 5J–L), the knockout mice showed
increased interest compared with their interest in the non-social
object (Time in the inside zone in Figure 5N vs. Figure 5P,
t = 4.548, P < 0.001). However, the CD157−/− mice resulted
in less entry into the inside zone (n = 8, t = 2.333, P < 0.01;
Figure 5O) and a shorter time spent in the inside zone (n = 8,
t = 3.135, P < 0.05; Figure 5P) compared with the wild-type
mice. The results to the novelty indicate that the CD157−/− mice
have a higher level of anxiety in the novel environment, as demon-
strated by a preference to be near a protective wall rather than
exposed to danger in the open field and lower sociability to the
novel non-social and social targets.
This anxiety-related behavior was confirmed using the light
and dark chamber test (Figure 6). The transition from the light
to dark arena was significantly different (Figures 6A,B). The
CD157−/− mice entered the dark chamber with an average fre-
quency of 2.2 ± 0.4 times during a 10-min test, while the
CD157+/+mice entered at a frequency of 8.6 ± 2.4 times dur-
ing the same time span (n = 8, P < 0.01; Figure 6C). While in
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FIGURE 5 | Anxiety and social preference tests in the open field with
adult male mice. Schemes of experiments illustrate the open field
without any object (A) or with a non-social target (G) or a social (male
mouse) target (J) in the center in the inside zone. Representative
movement tracks of the CD157+/+ and CD157−/− mice in the open field
with no object (B,C), with the non-social target (H,I) or with the social
target (K,L) over a 10-min period are shown. Percentage of time spent in
the inside zone (D), number of entries to the inside zone (E) and
average speed in the inside zone (F) with no object are shown. Number
of entries to the inside zone (M,O) and percentage of time spent in the
inside zone (N,P) with the non-social or social object are shown. The
blue bars represent the CD157+/+ mice, and the red bars represent the
CD157−/− mice. The data are expressed as the means ± s.e.m., n = 8,
∗P < 0.05 or ∗∗P < 0.01.
the light zone, the CD157−/− mice moved significantly more
slowly than the CD157+/+ mice (n = 8, P < 0.05; Figure 6D).
Reversely, when the mice were first placed in the dark arena prior
to initiating the experiments, the CD157−/− mice stayed in the
dark for a longer period of time (n = 10, data not shown). These
results indicate that the CD157−/− mice experience anxiety when
transitioning into a novel condition.
ANXIETY-RELATED BEHAVIORS AND RECOVERY
Next we applied the elevated plus maze test, the most standard-
ized experiment for measuring anxiety in a mouse model. As
shown in Figure 7, CD157−/− mice stayed only briefly in the
open arm (Figure 7A; P < 0.05) and longer in the closed arm
(P < 0.005), compared with the wild-type mice, with no dif-
ferences in total distance (Figure 7B), indicating anxiety-related
behaviors in the knockout mice.
To determine whether these anxiety-related behaviors
observed in CD157−/− mice can be rescued through pharma-
cological treatment, we examined diazepam (Altamura et al.,
2013), an anti-anxiety drug that activates GABAA receptors
and mirtazapine (Watanabe et al., 2011), a second-generation
anti-depressant with a combined serotonergic and noradrenergic
mechanism. Based upon preparatory experiments for deter-
mining drug doses, we used diazepam with a concentration of
1mg/kg in a single i.p. administration prior to 30min of testing,
or mirtazapine at 1mg/kg, i.p., once a day for 7 consecutive
days.
For time spent in open arms, One-Way ANOVA followed
by Bonferroni’s post-hoc test revealed a significant effect of the
drugs in CD157−/− mice [mirtazapine (n = 10) and diazepam
(n = 5); F(2, 18) = 5.251, P < 0.05; Figure 7C]. For time spent in
closed arms One-Way ANOVA followed by Bonferroni’s post-hoc
test showed the significant effects of these drugs in CD157−/−
mice [F(2, 18) = 8.495; P < 0.05 or P < 0.005, respectively]. Both
drugs rescued knockout mice to the behavioral level observed in
the untreated mice. The total distances moved in the apparatus
were not different in treated and untreated groups (Figure 7D).
These experiments indicate the anxiety behaviors are measurable
and robust in CD157−/− and pharmacologically reversible to the
control mouse level.
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FIGURE 6 | Behavior of wild-type (blue, +/+) or CD157 knockout (red,
−/−) mice in the light-dark transition test. (A) Representative traces of
both genotypes in the light compartment for the first 5min. The percentage
of time spent in the light compartment (B), transition numbers between
the two compartments (C) and the average speed in the light compartment
(D). The results are expressed as the means ± s.e.m. ∗P < 0.05 compared
with CD157+/+ group, n = 8.
DEPRESSION-LIKE BEHAVIOR AND RECOVERY
To make the lower movement activity during day and night
in knockout mice much clear, we examined depression-like
behaviors using tail suspension and forced swimming tests. We
observed a significant increase in immobility during the tail sus-
pension and forced swimming tests in CD157−/− adult male
mice compared with CD157+/+ mice [tail suspension, n = 20,
t = 2.583, P < 0.05 (Figure 8A); forced swimming, n = 10, t =
1.689, P < 0.05 (Figure 8B)].
Interestingly, the CD157−/− mice showed a peculiar behav-
ior. They took a significantly longer time to climb up the wall of
the swimming pool (t = 7.925, P < 0.001; Figure 8C). While this
climbing behavior was frequently observed during the first 2min
and quickly adapted and stopped struggling in the water in wild-
type mice, CD157−/− mice continued to attempt to climb the
wall from the start to the end of the observation period (6min) to
escape, potentially reflecting an altered emotional state.
In the tail suspension test, One-Way ANOVA followed by
Bonferroni’s post-hoc test revealed significant recovery to the lev-
els of wild-type mice or more in CD157−/− mice using the
two drugs [F(2, 27) = 27.904, P < 0.05, P < 0.001, respectively;
Figure 8D]. In contrast, immobility in the forced swimming test
was significantly rescued to the control level after treatment with
mirtazapine, but not diazepam, in CD157−/− mice [One-Way
ANOVA followed by Bonferroni’s post-hoc test; F(2, 22) = 4.627,
P < 0.05; Figure 8E]. The climbing time in the forced swim-
ming test was recovered from approximately 800–350% of the
levels in the untreated wild-type mice using both drugs [One-
Way ANOVA followed by Bonferroni’s post-hoc test, F(2, 22) =
10.167, P < 0.01 or 0.001, respectively; Figure 8F]. This result
shows that depression-like behavior is possible in CD157−/−
mice, which is reversible by classical and new types of anti-anxiety
or anti-depression drugs.
SOCIABILITY IN THE THREE-CHAMBER TEST
Although we had already performed tests of sociability using
novel targets in the open field test, to confirm the abnormal
sociability phenotype in CD157−/− mice, we used a more spe-
cific tool, a three-chamber box test (Figure 9). For these exper-
iments, a target male mouse was placed in the left chamber
(Stranger 1, Figure 9B), and a second target male mouse was
placed in the right chamber (Stranger 2, Figure 9C). The mice
displayed no significant side-preference during the habituation
phase (Figures 9A,D,G). Representative traces are shown for the
both types of mice during the sociability session (Figures 9B,E,H)
and the preference of social novelty session (Figures 9C,F,I).
There was no difference in the number of entries to the Stranger
1 chamber by the CD157−/− and CD157+/+ mice (n = 8;
Figure 9J). The number of entries to the chamber containing the
social target (Stranger 1) was equally and significantly higher than
the number of entries to the empty room [Two-Way ANOVA,
F = 73.673, P < 0.01; Figure 9J]. The percentage of sociabil-
ity, which was estimated from the percentage of time that the
mouse stayed in the target room, was also equally high for both
genotypes (n = 8; Figure 9K).
When the second target mouse was placed in the right cham-
ber, the number of entries to the new social target (Stranger 2)
chamber by the CD157−/− mice was lower than the num-
ber of entries made by the CD157+/+ mice [n = 8; Two-Way
ANOVA for effect of genotype, F = 11.057, P < 0.05; Figure 9L].
In addition, the numbers of entries for both mouse strains were
much higher than the numbers of entries to the room contain-
ing Stranger 1 (P < 0.05; Figure 9L). The percentages of time
spent with Stranger 2 were 51.6 ± 1.7% for CD157−/− mice vs.
67.1 ± 3.9% for CD157+/+ mice (n = 8, t = 3.067, P < 0.05;
Figure 9M). Therefore, it is reasonable to conclude that the
CD157−/− mice demonstrated the same level of sociability, with
social avoidance and/or decreased social preference.
RESPONSES TO FEAR AND STARTLE STIMULI
To confirm the sensory characteristics of the CD157−/− mice, we
measured their acoustic startle response. The startle response was
significantly elevated in the knockout mice compared with that of
the wild-type mice (0-db pre-pulse in Figure 10A; n = 10 in each
genotype, t = 2.183, P < 0.05). The CD157−/− mice exhibited
greater startle responses under almost all pre-pulse conditions
except for stimulation at 90 db (Figure 10B). In addition, sen-
sory disturbance was also observed during a fear-conditioning
paradigm (Figure 10C). The CD157−/− mice exhibited a longer
freezing time than did the CD157+/+ mice (n = 10 in each
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FIGURE 7 | Anxiety-related behavior of adult male mice in the elevated
plusmaze. (A) CD157−/− mice spent a significantly shorter time in open arms
(∗P < 0.05) and a longer time in closed arms (∗∗∗P < 0.005) compared with
CD157+/+ mice (n = 9–10 per group, t-test). (B) The total distance moved in
the elevated plus maze was not different between the two groups. (C) Effects
of diazepam (DZ, 1mg/kg, i.p.) and mirtazapine (Mir, 1mg/kg, i.p.) on
CD157−/− mice. Treatment with mirtazapine for 7 days significantly increased
the time spent in open arms in CD157−/− mice (n = 5–10 per group, One-Way
ANOVA followed by Bonferroni’s post-hoc test, ∗P < 0.05). Diazepam and
mirtazapine significantly decreased the time spent in closed arms for
CD157−/− mice (One-Way ANOVA followed by Bonferroni’s post-hoc test,
∗P < 0.05, ∗∗∗P < 0.005, respectively). (D) The total distances moved were
not different between the three groups. The data are expressed as the means
± s.e.m. The values are designated as 100% in non-treated wild-type mice.
genotype; conditioning, t = 3.195, p < 0.01; contextual, t =
2.404, P < 0.05), indicating that the knockout mice have a dis-
turbance in their attention or sensory gating.
ADP-RIBOSYL CYCLASE ACTIVITY
One important aspect addressed is that CD157 deficiency affected
the metabolism of oxytocin (OT), a well-known hormone sus-
pected to play a role in neuropsychiatric features (Higashida et al.,
2012a,b; Lee, 2012). The authors have previously shown that
deficiency in CD38 (another major member of the NADase/ADP-
ribosyl cyclase family that shares 30% homology with CD157
(Malavasi et al., 2008; Lee, 2012) was associated with a dramatic
decrease in plasmatic oxytocin leading to maternal and social
behavior alterations (Jin et al., 2007; Higashida et al., 2012a,b).
Therefore, we examined ADP-ribosyl cyclase activity
(Figure 11). There were no significant differences in ADP-
ribosyl cyclase activity between the two genotypes in the
hypothalamus (1584.1 ± 53.1 for CD157+/+ mice vs. 1509.2
± 71.5 pmol/min/mg protein for CD157−/− mice) and pitu-
itary (126.7 ± 17.2 vs. 106.3 ± 8.7 pmol/min/mg protein for
CD157+/+ and CD157−/− mice, respectively; Figure 11A).
We measured the plasma OT levels in both genotypes.
The plasma concentration of OT in CD157−/− mice
(457.1 ± 54.1 pg/ml, n = 6) was significantly lower than
that in CD157+/+ mice (623.5 ± 46.1 pg/ml, n = 6, P < 0.01;
Figure 11A).
RECOVERY OF SOCIABILITY BY OXYTOCIN
Based on our data from plasma OT levels, we tested the effects of
OT on impaired emotional behavior in CD157−/− mice. Here,
we used the newly reported simple two-step social interaction
test in the open field (Chaudhury et al., 2013). As shown in
Figures 11B,C, a clear social avoidance was detected inCD157−/−
mice, compared to CD157+/+ mice [n = 6–7, Two-Way ANOVA
for genotypes, F(1, 11) = 94.91, P < 0.0001]. CD157+/+ mice
showed significantly higher interactions than that in CD157−/−
mice with subcutaneous injection of PBS [n = 6–7, Two-Way
ANOVA for PBS, F(1, 11) = 28.59, P < 0.0001]. At 20min from
intraperitoneal injections of OT (100 ng/Kg of body weight),
the CD157−/− mice recovered to a level identical to that in
CD157+/+ mice [n = 6–7, Two-Way ANOVA for genotypes and
OT, F(1, 11) = 13.01, P < 0.0001].
CD157 IN THE AMYGDALA
We investigated the neurological cues underlying the anxiety-
related and depression-like behaviors in CD157−/− mice at the
tissue andmolecular levels. First, we examined the protein expres-
sion of CD157 in the adult brains of wild-type males using
a specific antiserum developed against CD157 (see Methods).
Consistent with the low level of CD157 mRNA expression in the
brain regions compared with the expression level in the spleens
of wild-type adults (Figure 12), weak but distinct immunoreac-
tivities were detected in the amygdala: the basolateral amygdaloid
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FIGURE 8 | Depression-like behavior in tail suspension and forced
swimming tests. (A) The time of immobility in the tail suspension test was
longer for CD157−/− mice compared with CD157+/+ mice (n = 20 per group,
∗P < 0.05). (B,C) The immobility or climbing time in the forced swimming
test was longer for CD157−/− mice compared with CD157+/+ mice (n = 10
per group, ∗P < 0.05 or ∗∗∗∗P < 0.001, respectively). The data are expressed
as the means ± s.e.m. (D–F) Depression-like behavior was recovered at
30min after a single i.p. administration of diazepam (DZ, 1mg/kg) or after
chronic administration of mirtazapine for 7 days (Mir, 1mg/kg, i.p.) in tail
suspension (D) or forced swimming (E,F) tests in CD157−/− mice. The data
are expressed as the means ± s.e.m. The values are designated as 100% in
non-treated WT mice (ANOVA followed by Bonferroni’s post-hoc test,
n = 5–10 mice per group; ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗∗P < 0.001,
respectively).
nucleus anterior region, the central amygdaloid nucleus and the
medial amygdaloid nucleus posteroventral region in CD157+/+
mice, but not in CD157−/− mice (Figures 13A,B). In other brain
regions, little or no immunoreactivity was detected (data not
shown).
Based on these observations, we macroscopically examined
the brains of these mice. Macroscopic abnormalities were not
obvious, and there was no difference in the wet weights of the
brains in the two genotypes (n = 20, 0.43 ± 0.4 g vs. 0.43 ± 0.2 g
for wild-type and knockout mice, respectively). Subsequently,
we microscopically observed the brains. Nissl staining was per-
formed on male brains, and no or less structural abnormalities
were observed in the regions of the brain tested, including the
cortex and the hippocampus, in CD157−/− mice (Figure 13C,
left panel). However, the amygdala regions seem to be altered
in CD157−/− mice, including the amygdalohippocampal area
posteromedial part (AhiPM), the posterior part of the baso-
lateral amygdaloid nucleus (BLP), the amygdalopiriform tran-
sition area (APir) and the posteromedial cortical amygdaloid
nucleus (PMCo; Figure 13C, right panel). Then, we compared
the amygdala between two genotypes by neuron-specific NeuN
staining (Figure 13D). The amydgala regions in the CD157−/−
mice seem to be smaller compared with those of the CD157+/+
mice. However, when the number of DAPI-stained nuclei was
measured in the PMCo, the cell density was approximately equal
in both genotypes: 193.3± 5.2 cells/μm2 for CD157+/+ mice and
204.5 ± 6.0 cells/μm2 for CD157−/− mice (t = 0.15, n = 5).
To gain a functional change of the amygdala in response
to environmental stimuli, we quantified the amount of c-Fos
immunoreactivity in the amygdala of mice from both genotypes
(Figure 13E). When the mice were exposed to the new environ-
ment in the open field test for 10min, c-Fos immunoreactive cell
number was less evident in CD157−/− mice than in CD157+/+
mice (n = 4, t = 7.212, P < 0.001; Figure 13F). These results
suggest that the amygdala is seemingly less developed and neurons
activated in the amygdala is impaired in the knockout mice.
DISCUSSION
Our results show that young adult male mice of 8- to 10-weeks old
with the CD157 (BST1) null mutation display robust and well-
replicated emotion-related behavioral phenotypes: CD157−/−
mice displayed severe anxiety-related behaviors for the novel envi-
ronment; CD157−/− mice also exhibited anxiety for non-social
and/or social novel targets; Weak sociability with novel target
mice and social avoidance for target males were also prominent
phenotypes. In addition, CD157−/− mice displayed depression-
like behaviors. All of these social behavior impairments in mul-
tiple paradigms seem to suggest psychiatric traits in CD157−/−
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FIGURE 9 | Sociability and social preferences of adult male mice in the
three-chamber apparatus. (A–I) Experimental schemes and representative
tracks of the CD157+/+ and CD157−/− mice in the sociability task when a
stimulus male mouse was placed in the left chamber (B,E,H) or in the social
novelty task when a new target male mouse was placed in the right chamber
(C,F,I). The number of entries into Stranger 1 and empty chambers (J) or the
Stranger 1 and Stranger 2 chambers (L), the percentage sociability (K) and
the social novelty (M) of the CD157+/+ (blue) and CD157−/− (red) mice are
shown. The data are expressed as the means ± s.e.m., n = 8, ∗P < 0.05,
∗∗P < 0.01, respectively.
mice, because the multiple tasks applied here are well-established
tools for use with animal models of human psychiatric disorders
(Crawley, 2008).
The anxiety-related behavioral phenotype detected by the
standard test for anxiety was fully reversed by diazepam, a
typical anti-anxiety drug, and the recently developed anti-
depressant drug, mirtazapine. Depression-like behaviors detected
by the tail suspension paradigm were reversed by diazepam,
and mirtazapine-treated animals recovered to a greater degree
than the control animals. The same phenotypic deficiencies seen
in the forced swimming test were not recovered by diazepam,
but were effectively rescued by mirtazapine. The phenotype of
climbing to the wall, which may also represent some sensory
deficit and be consistent with the altered state of fear observed
in CD157−/− mice (Figure 10), was markedly rescued by both
drugs. Such pharmacological intervention effectiveness suggests a
robust signal-to-noise disturbance in emotional phenotypes and
provides an easy replicable baseline for the therapeutic response
in CD157−/− mice. Although the data show slight sensitiv-
ity differences of drugs on both phenotypes, because we used
a single way of application and dose of drugs (Figures 7, 8),
it is too early to determine the detailed pharmacological fea-
tures of emotional phenotypes in the knockout mice. Genetic
rescue of the CD157−/− mice was admittedly not provided
here, likely because of comprehensible difficulties in infecting
and expressing the glycosylphosphatidylinisotol-linked molecule.
Genetic manipulations for rescue of phenotypes, such as brain
re-expressing of CD157 with the lenti-virus infection tech-
nique (Jin et al., 2007; Akther et al., 2013), would be more
confirmative.
We did not detect any apparent physical disability in young
adult CD157−/− mice under less influence of aging. When the
knockout mice were forced to move during foot printing or on
the rota rod, no apparent abnormality in coordinate motion or
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FIGURE 10 | Attention- and fear-related characteristics. (A) In a
pre-pulse inhibition paradigm based on the acoustic startle response,
CD157−/− mice exhibited an increased startle amplitude from 0-dB to
85-dB pre-pulse conditions (n = 10, ∗P < 0.05). (B) The ratio of inhibition in
CD157−/− mice did not differ from that of the CD157+/+mice up to the
85-dB condition, but the effect of inhibition was maintained with a 90-dB
pre-pulse. Note that the 90-dB pre-pulse was normally ineffective in the
CD157+/+ mice (n = 10, ∗P < 0.05). (C) The ratio of freezing in
CD157−/−mice was significantly increased in the conditioning and
contextual test phases of the fear conditioning paradigm. The data are
expressed as the means ± s.e.m. (n = 10, ∗P < 0.05 or ∗∗P < 0.01).
learning andmemory for themovement was detected. In contrast,
CD157−/−mice generally displayed less voluntary activities dur-
ing daily life with 24-h monitoring for 7 days in their home
cage, compared to home cages of wild-type mice (Figure 4). This
striking discrepancy in forced and voluntary movements, to our
knowledge, may be a characteristic behavioral measurement that
revealed a robust emotion-related disability in knockout mice.
Though current home cage recordings by the sensor beam did
not reveal how the mice behaved exactly, we estimated that they
squatted down in a single spot for long time, likely as a result of
an apathy state derived from depressive emotion in theCD157−/−
mice. The precise patterns of individual behavior should be val-
idated. On the other hand, interestingly, the day and night cycle
was the same as for control mice, indicating that the circadian
rhythm is likely not affected in CD157−/− mice.
Interestingly, several genome-wide association and meta-
analysis studies for PD have identified intronic single-nucleotide
polymorphisms (SNPs) in the CD157 (also known as BST1) gene
on human chromosome 4p15 as new susceptibility loci (Nalls
et al., 2011; Lill et al., 2012; Noyce et al., 2012), although one
may argue that the CD157 common SNPs provide not large risk.
Additional genetic and environmental factors may thus be needed
to unravel a pathogenic role of CD157 genetic modification or
deletion (Chen et al., 2013).
The neuropsychiatric comorbidities in PD have not inten-
sively been studied in an appropriate animal model (Dawson
et al., 2010; Campos et al., 2013), although anxiety has been
observed in conventional neurotoxin-treated rats and mice and in
Parkin-deficient mice (Branchi et al., 2008; Dawson et al., 2010;
Rane et al., 2012; Campos et al., 2013). It is of interest to test
if these behavioral impairments in CD157−/− mice likely reflect
impairment of the amygdala (Harding et al., 2002; Surdhar et al.,
2012). However, there is no direct evidence that CD157 plays a
role in neuronal migration during neurogenesis, although CD157
binds integrins in human monocytes (Lo Buono et al., 2011,
2014) and plays a role in neutrophil migration (Quarona et al.,
2013). Our preliminary results show that CD157 is expressed
in nestin-positive neural stem cells near the brain ventricular
zone. Therefore, it is likely that a CD157 deficiency might cause
amygdala’s abnormalities.
Recently, it has been estimated that abnormalities in addi-
tional neuronal regions rather than the nigrostrial region are
potentially involved in PD progression and may contribute to
the appearance of non-motor symptoms, such as anxiety, depres-
sion, olfactory and memory impairment, sleep abnormalities and
gastrointestinal disturbances (Tadaiesky et al., 2008; Wattendorf
et al., 2009; Starkstein et al., 2013; Storch et al., 2013). Anxiety
and depression are the earliest PD manifestations, and patients
with high anxiety are at an increased risk for PD (Richard,
2005; Drijgers et al., 2010; Schrag and Leentjens, 2012). The
underlying biological mechanisms that lead to these symp-
toms during any stage of the disease, including the pre-motor
phase, are unknown (Prediger et al., 2012; Storch et al., 2013).
Therefore, it is reasonable that our current experiments were
designed to examine emotion-related phenotypes in the time
window of 8- to 10-weeks-old. Further validation is necessary to
determine a relationship between emotion-related phenotypes in
CD157 knockout mice and any small aspects of human emotion
phenotypes in PD.
At present, we cannot explain the discrepancy between plasma
and hypothalamic levels of OT (Figure 11). As the majority of OT
neurons release OT into the blood, we speculate that the release
of OT from axon terminals in the pituitary may be attenuated
in CD157 knockout mice without detectable changes in OT
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FIGURE 11 | ADP-ribosyl cyclase activity, oxytocin levels and social
avoidance in the open field test. (A) Plasma OT levels in CD157+/+ mice is
higher than those in CD157−/− mice (n = 6, ∗∗P < 0.01, Student t-test).
ADP-ribosyl cyclase activity measured with formation of cyclic GDP-ribose in
the hypothalamus and pituitary in CD157+/+or CD157−/−mice (n = 6). (B) A
schematic drawing of the social interaction test. The social target (a male
mouse) was placed in the center immediately after a 10-min habituation.
Representative track traces of CD157+/+ and CD157−/− mice treated with or
without PBS or OT (100 ng/kg of body weight, i.p.). (C) Time spent in the inside
zone measured over 10min in CD157+/+ and CD157−/− mice treated with or
without PBS or OT. The data are expressed as the means ± s.e.m. [n = 6–7,
Two-Way ANOVA for genotypes and OT, F(1, 11) = 13.01, P < 0.0001].
FIGURE 12 | RT-PCR analysis of CD157 mRNA expression levels in the
four brain regions and spleens of mice using β-actin mRNA as an
internal control. The quantitative data are expressed as the means ±
s.e.m. (n = 5 independent experiments of CD157 /actin). ∗∗∗∗P < 0.001
from the striatum, Student t-test. Abbreviations used: Cbr, cerebrum; Cbl,
cerebellum; Hyp, hypothalamus; Str, striatum; Spl, spleen.
contents in the hypothalamic nuclei, which are enriched in OT.
It is clear that OT neurons project concomitantly to the poste-
rior pituitary and brain regions controlling fear responses, such
as the central amygdala (Knobloch et al., 2012; Knobloch and
Grinevich, 2014). Therefore, CD157 may directly or indirectly
affect the central axonal release of OT. The observed alteration of
the OT system (plasma concentrations) and compensatory effects
of OT on behaviors provide clinically and therapeutically relevant
insights.
An alternative scenario underlying the contribution of OT in
CD157 knockout mice is disruption in OT signaling in the brain.
To investigate this issue, data regarding expression of OT recep-
tors in the relevant brain areas are required. In a preliminary
experiment, we measured the OT receptor mRNA levels in the
amygdala (n = 5). Unfortunately, we failed to detect any differ-
ences in OT receptor mRNA level in either genotype. Further
detailed analyses are required to determine the mRNA and pro-
tein levels of molecules related to OT signaling in each subregion
of the amygdala.
There is controversy regarding whether peripherally admin-
istered OT can efficiently penetrate the blood–brain barrier
(Churchland and Winkielman, 2012; Ludwig et al., 2013).
Therefore, the precise mechanism underlying the action of OT
in the present study remains unclear. However, numerous stud-
ies in rodents and humans have shown convincing pro-social
effects of OT applied peripherally, including intranasal applica-
tion (Neumann et al., 2013; Striepens et al., 2013; Watanabe et al.,
2014).
In conclusion, we have shown that CD157 plays a role in the
brain. Taken together with previous reports (Ishihara andHirano,
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FIGURE 13 | CD157 expression in the amygdala. (A,B) Representative
photos display CD157 immunoreactivity (green, indicated by arrows) in
the basolateral amygdaloid nucleus anterior part (BaL), or central
amygdaloid nucleus (CeL) and medial amygdaloid nucleus posteroventral
part (MeV) of adult male CD157+/+ or CD157−/− mice. Hoechst-stained
nuclei are shown in blue. The insets are enlarged areas indicated in
lower-magnification photos. The scale bar represents 100μm. (C)
Nissl-stained coronal sections of CD157−/− mice (anteroposterior position
at Bregma −3.08mm). Magnified images of the amygdala, marked with a
black square, is shown to the right. The amygdala, including the
amygdalohippocampal area posteromedial part (AhiPM), the posterior part
of the basolateral amygdaloid nucleus (BLP), the amygdalopiriform
transition area (APir) and the posteromedial cortical amygdaloid nucleus
(PMCo) are indicated. Scale bar: 200μm. (D) NeuN-immunostained cells
(neurons) are shown in green, and Hoechst-stained nuclei are shown in
blue in CD157+/+ or CD157−/− mice. Scale bar: 200μm. (E) c-Fos
immunostaining in the amygdala in mice exposed to the new
environment in the open field test for 10min. Photomicrographs of
coronal sections showing c-Fos immunoreactivity as Alexa 488
fluorescence. (F) The number of c-Fos-immunoreactive cells in the
amygdala in CD157+/+ or CD157−/− mice as in (E). The data are
expressed as the means ± s.e.m. (n = 4, ∗∗∗∗P < 0.001).
2000; Yilmaz et al., 2012; Quarona et al., 2013), these observa-
tions indicat that CD157 has multiple functions in a variety of
tissues. The present findings support the novel suggestion that
CD157 can be defined as a neuro-entero-immunological regulator,
which is important when considering the biological significance
of the products, including cyclic ADPR, of the CD38 family. The
lack of differences in ADP-ribosyl cyclase activities in two dis-
tinct areas of the brain observed in the present study may be
the result of a reciprocal surrogate role played by other members
of the same family. Therefore, further experiments using double
CD38/CD157 knokout mice are required to address several of the
remaining open questions. Future studies may include validation
to support the link between the intronic common CD157 SNPs
and the emotion phenotypes relevant to anxiety or depression
observed during the premotor phase that precedes classical motor
features in PD patients.
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